We established an imaging protocol targeting the dopamine transporter in common marmoset monkeys by 123 I-FP-CIT SPECT. High resolution imaging was achieved with an upgraded clinical SPECT camera and a 3T MRI system. Combination of 123 I-FP-CIT SPECT and high resolution MRI allows for the detection of small dopaminergic brain structures. The presented method is a suitable imaging tool to be used in a marmoset monkey model of Parkinson's disease.
Introduction
Parkinson's disease (PD) is a disabling neurodegenerative disease characterized by progressive neuronal cell loss and degeneration of nerve terminals of the nigro-striatal dopaminergic system (Dauer and Przedborski, 2003) . Single photon emission computed tomography (SPECT) is a valuable technique for clinical diagnosis and for studying the pathogenesis of PD, e.g. by quantifying the decrease of dopamine transporters (DATs) in the striatum. As demonstrated in many clinical trials, a reliable marker to image DATs is the ␥-emitting radioiodinated cocaine analog 123 I-N--fluoropropyl-2␤-carbomethoxy-3␤-{4-iodophenyl}-nortropane ( 123 I-FP-CIT) (Baldwin et al., 1995; Neumeyer et al., 1994; de la Fuente-Fernández, 2012) .
There is an increasing demand for in vivo imaging applications at the level of preclinical and translational research using non-human primates (NHPs), especially for long-term studies in animal models of Parkinson's disease. Traditionally, the most commonly used NHP species in PD research are Old World monkeys (OWMs), such as baboons, rhesus and cynomolgus monkeys, (Baldwin et al., 1995; Booij et al., 1997; Prunier et al., 2003; Laruelle et al., 1993; Ma et al., 2002) .
Despite less frequent usage, the common marmoset monkey (Callithrix jacchus), a New World monkey species, provides a highly attractive model for preclinical research in PD. The common marmoset monkey is a small, day-active, NHP that is native to Brazil. The animals are not threatened or endangered in the wild and breed well in controlled laboratory conditions. They have a small body size of around 25 cm in length and a weight of 300-450 g (Mansfield, 2003) . Depending on the topic or substance under investigation, utilization of marmoset monkeys can prove advantageous over other species. This is the case, for example, when pharmacological agents for prospective use in humans cross react with marmoset -but not with macaque or baboon -binding sites and/or when the generation of test substances is extremely expensive. Due to their much lower body mass relative to OWMs, generally less than 1/10th of a test substance is needed in the marmoset compared to OWMs (Mansfield, 2003; Orsi et al., 2011) .
Since the development of pinhole and multi-pinhole collimation (Beekman and van der Have, 2007; Schramm et al., 2003) , considerable progress has been made in small animal SPECT imaging in the field of Parkinson's disease (Booij et al., 2002; Andringa et al., 2005; Lauwers et al., 2007; AlvarezFischer et al., 2007) . Nevertheless, only Saji and colleagues have performed a PD-related brain SPECT study using common marmosets and two radiotracers the 123 I-2␤-carbomethoxy-3␤-(4-iodophenyl)tropane ( 123 I-␤-CIT) and 123 I-iodobenzamide ( 123 I-IBZM) (Saji et al., 2003) .
To the best of our knowledge, 123 I-FP-CIT SPECT has not been applied in marmosets. Yet, future preclinical models utilizing this technology have a high translational value since 123 I-FP-CIT SPECT is well established in clinical diagnostics. Therefore, the aim of this study was to establish an imaging protocol for 123 I-FP-CIT SPECT in common marmoset monkeys and to validate its use in the unilateral 6-OHDA model of PD.
Materials and methods

Animals
Three adult (3, 5 and 12 years old) male common marmoset monkeys (Callithrix jacchus) (350-450 g) were used in this study (Table 1) . The animals were obtained from the breeding colony at the German Primate Center (Göttingen, Germany) and pair-housed in a temperature-(25 ± 1 • C) and humiditycontrolled (65 ± 5%) facility under a 12-h day/night cycle. Each cage (80 cm × 150 cm × 66 cm, Ebeco GmbH, Castrop-Rauxel, Germany) was furnished with wooden branches and shelves and contained a wooden sleeping box (24 cm × 21 cm × 18 cm). The animals were fed ad libitum with a pelleted marmoset diet (ssniff Spezialdiäten, Soest, Germany). In addition, 20 g mash per animal was served in the morning and they received 30 g clean-cut fruits or vegetables mixed with noodles or rice in the afternoon. Water was always available. All animal experimentation was carried out in accordance with the European Council Directive of November 24 1986 (86/EC) including Position 6106/20 of the EU Council of May 26 2010, and was approved by the Lower Saxony Federal State Office for Consumer Protection and Food Safety, Germany.
Pharmacokinetic study
The pharmacokinetic characterization was carried out on two separate occasions in a single animal (marmoset #1) under general anesthesia. Anesthesia was initiated by intramuscular injection of diazepam (0.3 mg/kg, Diazepam ® , Ratiopharm, Germany), alfaxolon (10 mg/kg, Alfaxan ® , Vetoquinol, UK) and glycopyrronium bromide (0.01 mg per animal, Robinul ® ; Riemser, Germany). Subsequently, the animal was intubated with a polyethylene endotracheal tube (inner/outer diameter = 1.3/2.2 mm) and kept under inhalation anesthesia (0.4-1.0% isoflurane in 70:30 N 2 O O 2 ). The animal received an intravenous injection into the right saphenous vein of approximately 60 MBq of 123 I-FP-CIT (Datscan ® , Amersham Buchler, Braunschweig, Germany). The radioactivity in the injection syringe was measured immediately before and after injection with an automated gamma counter (PerkinElmer, Wizard 3, Waltham, MA, USA) to correct the injected dose for physical decay. Repeated examinations of one animal yielded 138.1 (test) and 150.7 kBq/g bodyweight (re-test) of 123 I-FP-CIT.
Blood samples were obtained from the left saphenous vein 5, 15, 30, 60, 120, 180, 210 and 240 min post injection, followed by plasma centrifugation. Arterialisation of venous blood was achieved by hyperthermia in the animal's lower extremities, induced by a thermostat-controlled infrared radiator. Radioactivity values in blood plasma were corrected for physical decay from t = 0. The time course function x t = a 1 + a 2 × e (−k×t) was fitted to the measured plasma radioactivity values (m t ) in order to calculate the initial slope/rate constant of decay and the steady state radioactivity. The radioactivity at the time of injection (x t = 0 = a 1 + a 2 ) was calculated from the injected dose and the volume of extracellular fluid, which was assumed to be 25% of the body mass (Swan et al., 1954 fluid and that there is a free exchange of 123 I-FP-CIT between intraand extra-vasal extracellular fluid. The method of minimizing the weighted sum of squares of deviations 0→t (m t − x t ) 2 was used. Weight was set to 1/(m t ) 2 . Curve fitting was performed using Sigmaplot 11 (Systat Software, Germany). In parallel with blood collection, serial SPECT images were taken to monitor 123 I-FP-CIT brain uptake (see below).
Brain SPECT
SPECT imaging was performed using a three-headed gamma camera (Prism 3000XP, Picker International, Cleveland, OH, USA) upgraded with a dedicated small-animal imaging module (HiSPECT, Scivis, Göttingen, Germany). Each collimator head was equipped with a pyramidal collimator and multi-pinhole aperture plate (6 pinholes). The inner diameter of each pinhole was 2.5 mm, which yielded a tomographic resolution of 2.1 mm and an average on axis sensitivity of 960 cps/MBq. The field-of-view (FoV) was 143 cm 3 . Images were acquired at 256 × 256 projection matrices with a pixel size of 1.78 mm over 10 gantry steps (30 projection angles) in a step-and-shoot mode. Up to 4 energy windows were acquired. An acquisition time of 175 s per gantry step was chosen for timeactivity analysis (marmoset #1) resulting in a total scan time of 29.8 min. To obtain high quality images, as done for the 6-OHDAlesioned (marmoset #2) and control animal (marmoset #3), a longer acquisition time was chosen (300 s per angle and total scan time of 50.2 min). The photo peak energy was set to 159 keV with a window of ±10%. Multi energy window scatter correction was applied. The anaesthetized animals were placed in a custom-made holder in prone position and the head was fixed with ear bars. Standard image acquisition (marmosets #2 and #3) was initiated after reaching equilibrium state 2 h after injection of 50-60 MBq 123 I-FP-CIT. In the pharmacokinetic study (marmoset #1), image acquisition was started immediately after application of the tracer.
SPECT reconstruction and evaluation
SPECT reconstruction was performed using a dedicated iterative ordered subset expectation maximization (OSEM) algorithm consisting of three iterations and four subsets per iteration (HiSPECT ® , Scivis, Göttingen, Germany). The reconstructed voxel size was 0.6 mm 3 . For quantification, brain activity was determined with HiSPECT software. For time-course analysis (animal # 1), rectangular shaped regions of interest (ROIs) of 74 mm 3 volume were set manually for the left (STl) and right striatum (STr) and cerebellum (CB) in reference to the corresponding MRI. 123 I-FP-CIT brain uptake was given as (Bq/l). Activities of left and right striatum were averaged (ST = (STl + STr)/2). Specific binding in the ST was calculated by subtracting the mean activity in the CB from the mean activity in the ST and dividing the result by the mean activity in the CB, i.e. (ST-CB)/CB. For the 6-OHDA-lesioned and control animal (animals #2 and #3), ROIs of 370 mm 3 volume were chosen in ST and CB with standard image acquisition. The binding ratio was calculated separately for left and right striatum. A ROI with a volume of 95 mm 3 was chosen for the midbrain area (substantia nigra and ventral tegmental area). The binding ratio of the midbrain area was calculated analogous to ST.
Magnetic resonance imaging (MRI)
MRI was performed on a 3T clinical MR system (Magnetom TIM TRIO, Siemens Healthcare, Erlangen, Germany) using an 8-channel receive coil designed for the human wrist. Marmosets were scanned in supine position under general anesthesia with diazepam (0.3 mg/kg i.m., Diazepam, Ratiopharm, Germany), alfaxolon (10 mg/kg i.m, Alfaxan ® , Vetoquinol, UK) and glycopyrronium bromide (0.01 mg per animal i.m., Robinul ® ; Riemser, Germany). The total measurement time for structural MRI was about 10 min, thus eliminating the need to intubate the animal.
Structural MRI with T1-w(eighted) and T2-w(eighted) contrast was performed at 0.4 mm isotropic resolution with non-selective excitation. The three-dimensional (3D) imaging volume covered the head and upper chest with the read-out direction along the body axis. The FoV in the right-left ventral-dorsal direction was 51.2 mm.
T1-w contrast was achieved by magnetization-prepared rapid acquisition of gradient echoes (MP-RAGE) using parameters recommended for humans (inversion time TI = 0.9 s, flip angle ˛ = 9 • , bandwidth BW = 200 Hz/pixel, echo time TE = 4.06 ms, repetition time TR = 2.25 s,) (Jack et al., 2008) , notwithstanding minor putative differences in T1 (Bock et al., 2009 ). The matrix of 320 × 128 × 128 was acquired in 4:18 min.
T2-w 3D turbo spin-echo (TSE, not shown) with variable flip angles (2 averages with phase partial Fourier, slice turbo factor of 2, yielding an echo train length of 75, effective TE = 278 ms at BW = 355 Hz/pixel; TR = 2.9 s). The matrix of 256 × 128 × 128 was acquired in 5:26 min.
Post-processing of imaging data
The 2D digital imaging and communications in medicine (DICOM) MRI images in axial-to-coronal orientation were converted to 3D neuroimaging informatics technology initiative (NIFTI) volumes, changing from the radiological right-left convention to left-right convention of the SPECT images. The T1-w volume was aligned to a custom-made T1-w template of the marmoset head and interpolated to 0.25 mm resolution in order to achieve consistent angulation of the horizontal plane. This was defined by the intercommisural line, as featured in the stereotaxic atlas of the National Institute of Neuroscience, Japan (Yuasa et al., 2010) . This T1-w volume then served as an individual anatomical reference to align the T2-w and SPECT data, using the FMRIB software library (FSL 4.1, Center for Functional Magnetic Resonance Imaging of the Brain, University of Oxford, UK, www.fmrib.ox.ac.uk/fsl). For spatial alignment, the FSL linear registration tool (FLIRT), was used to determine the 3D rigid body transform (6 parameters) by a mutual information criterion. A pixel mask of the brain was defined by the characteristic T1-w and T2-w intensities of the brain, followed by manual editing using FSLview.
Unilateral 6-hydroxydopamine lesion
The animal (marmoset #2) was given unilateral 6-hydroxydopamine (6-OHDA) injections into the nigrostriatal bundle according to the protocol of Annett et al. (1992) . To protect the noradrenergic and serotonergic pathways from the toxic effects of 6-OHDA, the marmoset was pre-treated with the noradrenalin (NA) uptake blocker talsupram (Lundbeck, Copenhagen, Denmark; 20 mg/kg) (Arnt et al., 1985) and the serotonin uptake blocker citalopram (Lundbeck, 5 mg/kg) (Hyttel, 1982) in sterile solution subcutaneously 30 min prior to the injections of 6-OHDA. Surgery was carried out under Alfaxalon/Alfadolon anesthesia (Saffan, Schering-Plough Ltd.; 18 mg/kg) and Diazepam (0.05 mg per animal) anesthesia and aseptic conditions. 6-OHDA [8 mg/ml free base weight 6-OHDA hydrobromide (Sigma-Aldrich, Steinheim, Germany) dissolved in 0.01% ascorbate-saline] was injected stereotactically into four sites within the nigrostriatal bundle on one side of the brain (coordinates: first site: 2 l at AP+6.5; L+1.2, V+6; second site: 2 l at AP+7, L+2.2, V+6.5; third site: 2 l at AP+7, L+2.2, V+7.5; and fourth site: 3 l at AP+6.5; L+3.2, V+7.5; according to Stephan et al. (1980) . The 6-OHDA was freshly prepared and stored on ice just before use. Each injection of 6-OHDA was made at a rate of 0.5 l/min using a 24-gauge injection needle, which was left in place for a further 4 min after each injection had been made. Following surgery, the monkey was given an analgesic and kept in a warm incubator until it was well enough to be returned to its home cage. Postoperatively, the animal was treated with meloxicam (0.2 mg/kg i.m., Metacam ® ,Boehringer Ingelheim, Germany) for 3 days and enrofloxacin (5 mg/kg i.m., Baytril ® , Bayer, Germany) for 5 days. Before the lesioning, the hand preference of the animal was assessed using the staircase test (see below) and the animal was injected with 6-OHDA on the contra-lateral side of the preferred hand in order to maximize the effect of motor impairments.
Behavioral test: the staircase task
The staircase task is a behavioral test to assess skilled forelimb reaching and was adapted to marmoset monkeys by Eslamboli et al. (2003) . A single animal (marmoset #2) was tested in the staircase task. This test requires the animal to collect small baits arranged on a series of five steps either ascending toward the midline (staircase hill) or descending toward the midline (staircase valley). The test apparatus is made of clear Plexiglas fixed to the front of the home cage during testing. Thus, the animal is tested in a familiar environment and handling is not required. The monkey is trained to reach through a vertical slot on the left or right side of the Plexiglas apparatus in order to retrieve small gum arabic pieces (∼5 mm 3 ), so both hands are needed for the successful completion of the task. The monkey was presented with 2 trials for each test (staircase hill and staircase valley). The success rate of the coordinated hand movements were scored as follows: grabbing and eating the reward was scored with 1-5 points, depending on the distance of the stair from the vertical slot. The reward on the nearest staircase was worth 1 point and the most distant was worth 5 points. In many cases, the animal needed several attempts until he could finally obtain the gum arabic pieces. Thus, if the animal could remove and eat the reward at his first attempt, then the corresponding score was doubled. The maximum possible scores were 28 and 30 for the staircase hill and staircase valley test, respectively. The scores of two trials were averaged. The monkey were trained pre-lesion until he was familiar with the apparatus and could readily retrieve the gum arabic pieces from all steps. During this period, it also became evident which was the preferred hand for the individual animal, so the subsequent lesion was made in the contra-lateral hemisphere. The animal was trained for the task for 6 months before lesioning. After the lesion, he was tested twice a month for two years and then once a month for 3 years. Importantly, the animal was not food-or water-deprived prior to the test. 
Results
Dose determination
The mean activity applied in the present study was 56.9 ± 6.3 MBq [I-123]-FP-CIT (corresponding to 130.7 ± 19.1 kBq/g bodyweight). In our experience, a suitable concentration ranges between 50 and 70 MBq (100-170 kBq/g bodyweight, data not shown). Concentrations above 70 MBq (170 kBq/g bodyweight) were not tested. The uptake of 123 I-FP-CIT in the brain was insufficient at concentrations below 30 MBq (<80 kBq/g bodyweight, data not shown). No adverse effects of the tracer were observed. 123 I-FP-CIT SPECT images of the common marmoset superimposed on T1-w MRI. The high tracer uptake in the striatum matches with anatomical structures in the control animal (animal #3) (upper row). Unilateral 6-OHDA lesioning of the nigro-striatal forebrain bundle leads to complete loss of striatal DAT activity (animal #2) (lower row, lesion is indicated by arrows). Acquisition time of SPECT images: 50.2 min.
Pharmacokinetic study
Serial SPECT images were obtained to describe the distribution kinetics of 123 I-FP-CIT in the marmoset brain. Shortly after i.v. injection of 123 I-FP-CIT, the whole brain was flooded with the tracer. The unbound tracer washed out over time, revealing a high and stable uptake of 123 I-FP-CIT in the striatum after about 50 min (Figs. 1 and 2A) . The calculated striatal to cerebellar binding ratios increased with time and reached highest values at 4 h after injection of the tracer (Fig. 2B) . Considering the stable plateau of striatal 123 I-FP-CIT uptake, the optimum acquisition time-point was determined to be between 2 and 4 h after application of the radioligand.
Analysis of blood samples showed that 123 I was eliminated within a few minutes following application. Thirty minutes after injection, the plasma activity declined on average to 4.1% of the administered activity and remained stable until the end of the measurement after 4 h (Fig. 2C) .
DAT scans of control and 6-OHDA-lesioned animals
High uptake of 123 I-FP-CIT was observed in both striata in the control animal, perfectly matching with the corresponding anatomical structures as revealed by the overlay onto MRI (Fig. 3) . The highest 123 I-FP-CIT uptake was observed in the more rostral parts of striatum, where the signals from caudate nucleus and putamen (referred to as caudatoputamen) could not be separated without the anatomical information of the underlying MRI. The DAT signal was less intense in the caudal part of the striatum. Calculated binding ratios revealed values of 2.94 for the left and 2.70 for the right caudatoputamen (Fig. 5B) . The high sensitivity of SPECT in combination with the high resolution of MRI even enabled the detection of small dopaminergic midbrain structures (Fig. 4) . Quantification of the signals in the substantia nigra together with the ventral tegmental area yielded a binding ratio of 1.91.
The suitability of DAT imaging was also tested in the unilateral 6-OHDA lesion model of PD as a proof of principle. Injections of 6-OHDA into the nigro-striatal projection pathway resulted in complete loss of striatal DAT binding (Fig. 3) , which was accompanied by overt behavioral deficits (Fig. 6) . Quantification of 123 I-FP-CIT uptake revealed binding ratios of 4.73 for the untreated contra lateral side and 0.09 for the lesioned side (Fig. 5A) . DAT scans were taken eight years after lesion, proving long-lasting chronic effects of 6-OHDA in this model. Fig. 6 . Long-term behavioral assessment of a 6-OHDA-lesioned monkey (animal #2). After lesioning, the animal failed to score in the staircase hill (A) and staircase valley test (B) when using the affected left hand (filled circles). Motor impairment remained chronic for at least 5 years.
Behavioral analysis
Before surgery, the animal showed similar scores for the left (26.72 ± 1.54) and right hand (26.06 ± 1.94) in the staircase hill task (Fig. 6A) . Following 6-OHDA lesioning, the animal's left hand fine motor skills were severely impaired and the animal could not complete the task with this hand (1st year score: 1.1 ± 1.64). In contrast, when using the right unaffected hand, the average annual score (1st year: 25.08 ± 3.54) was similar to the pre-lesion values. Fine motor skill impairments of the left hand remained stable over a time period of 5 years (2nd year: 0.13 ± 0.39, 3rd year: 0.11 ± 0.40, 4th year: 0.14 ± 0.45, 5th year: 0.23 ± 0.83). As expected, fine motor skills of the right hand were not affected by lesion and remained in the control range over the years (average annual scores: 2nd year: 24.6 ± 2.73, 3rd year: 25.18 ± 4.79, 4th year: 25.73 ± 1.55, 5th year: 25.88 ± 2.32).
Pre-lesion scores were similar for the left (29.11 ± 1.45) and right hand (27.0 ± 3.79) in the stair case valley task (Fig. 6B) . After surgery, a strong decrease in the average annual score was observed for the left affected hand (1st year: 1.56 ± 2.94). The score remained low over the following 3 years (2nd year: 0.03 ± 0.11, 3rd year: 0.0, 4th year: 1.91 ± 3.20), but slightly increased in the fifth year (5th year: 7.0 ± 5.47). In contrast, fine motor skills of the right hand remained unaffected throughout the entire experiment and no change in the scores of this hand was observed (1st year: 25.32 ± 3.78, 2nd year: 24.63 ± 5.32, 3rd year: 27.18 ± 2.82, 4th year: 26.73 ± 4.1, 5th year: 25.88 ± 3.83).
Discussion
The aim of this study was to establish DAT imaging in the common marmoset using 123 I-FP-CIT SPECT. Here, we used clinical equipment specially adapted for high resolution scanning of marmoset monkeys.
Pharmacodynamic time course analysis showed high and stable striatal binding of 123 I-FP-CIT for at least 4 h, indicating high specificity of 123 I-FP-CIT for DAT (Laruelle et al., 1993; Lundkvist et al., 1995) . Similar patterns of brain uptake were reported for humans (Kuikka et al., 1995) , Old World monkeys (Baldwin et al., 1995; Lundkvist et al., 1995; Booij et al., 1997) and rodents (Booij et al., 1997 (Booij et al., , 2002 Alvarez-Fischer et al., 2007) , suggesting universal applicability of 123 I-FP-CIT SPECT for DAT-related diseases. The individual differences in binding ratio between the unaffected contra lateral side of the 6-OHDA-lesioned animal and the control animal are within range of previously reported studies (Booij et al., 2002; Andringa et al., 2005) . KD binding experiments were not performed in the present study. However, the specificity of 123 I-FP-CIT for DAT and its suitability for PD diagnostics has been proven in other studies (Seibyl et al., 1998; Booij et al., 1998; de la Fuente-Fernández, 2012) .
Measurements of 123 I-FP-CIT activity in plasma of common marmosets demonstrated that the elimination of the radioligand from plasma share the same kinetics as in humans (Booij et al., 1998) and is similar to the elimination kinetics of 11 C-␤-CIT-FP in cynomolgus monkeys (Lundkvist et al., 1995) . Lipophilic radioiodinated plasma metabolites may marginally interfere with SPECT quantification (Lundkvist et al., 1995; Bergström et al., 1996; Heinz et al., 1997) .
Although the DAT scans did not feature sufficient anatomical detail to outline nuclear territories of the basal ganglia, the global intensity pattern could be robustly aligned to high-resolution structural MRI scans. Thus, ROIs of single deep brain nuclei can be defined for specific analysis and monitoring of concomitant volumetric changes. Our co-registration approach employed the intercommisural line as stereotaxic reference to ensure comparability between scans of the same animal as well as consistent display of different individuals.
Unilateral 6-OHDA injections into the nigro-striatal projection pathway led to complete loss of striatal DAT binding. This result corresponds well to the behavioral impairments of fine motor skills which were clearly detectable over 5 years following lesioning. Thus, the in vivo imaging and behavioral data exemplify the chronicity of the lesion protocol. These results are supported by other behavioral and histological data obtained after 6-OHDA applications in marmosets (Annett et al., 1994; Eslamboli et al., 2003) . 123 I-FP-CIT SPECT was evaluated in various rodent models of PD (Lauwers et al., 2007; Andringa et al., 2005; Alvarez-Fischer et al., 2007; Booij et al., 2002) . Until now, the only study that applied DAT SPECT to common marmosets was a reported by Saji and colleagues, who evaluated 123 I-␤-CIT in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD (Saji et al., 2003) .
In future studies, 123 I-FP-CIT SPECT may be an addition or alternative to behavioral assessments in non-human primate models of PD. Long-term monitoring in vivo by SPECT imaging would be especially advantageous in viral vector-mediated alpha-synuclein expressing approaches, in which parkinsonian symptoms slowly develop (Kirik et al., 2003; Eslamboli et al., 2007) . Especially, future therapeutic approaches in marmoset models of PD will benefit from longitudinal studies of individual disease courses, thus increasing the relevance and impact for translational research.
Conclusion
The presented work provides the first 123 I-FP-CIT SPECT protocol for application in common marmoset monkeys. The upgraded human scanner used in the present study, allows for future longterm and translational approaches. High resolution 123 I-FP-CIT SPECT and MR imaging appears to be a suitable combination for investigating DAT integrity and individual morphology in marmoset models of PD.
